Tag Archives: Roche’s

FiercePharmaAsia—COVID-19 drug manufacturing; Roche’s China slowdown; Astellas’ Iota buy

Takeda and CSL Behring are scaling up manufacturing of their coronavirus hyperimmune drug, but its reliance on blood donations could be a bottleneck. Eli Lilly has signed on Fujifilm to help make its COVID-19 antibody therapy as part of a Bill & Melinda Gates Foundation initiative to bring drugs for low- and middle-income countries. Roche blames… Read More »

Sanofi’s Eloctate, a Bioverativ buyout centerpiece, suffers on Roche’s Hemlibra launch

Sanofi has been among the pharma companies hardest hit by U.S. pricing pressure in diabetes, and now, competition is taking a toll on a prized asset from its $ 11.6 billion Bioverativ buyout. In the first quarter, hemophilia drug Eloctate’s sales of €174 missed consensus estimates of €204 million by 14.7%, ODDO BHF analysts wrote in… Read More »